中国神经再生研究(英文版) ›› 2026, Vol. 21 ›› Issue (4): 1339-1352.doi: 10.4103/NRR.NRR-D-24-01124

• 综述:退行性病与再生 • 上一篇    下一篇

内质网应激的未折叠蛋白反应在视网膜退行性疾病中的作用

  

  • 出版日期:2026-04-15 发布日期:2025-07-25
  • 基金资助:
    陕西省自然科学基金(重点项目)(2021JZ-60)

Unfolded protein response in endoplasmic reticulum stress associated with retinal degenerative diseases: A promising therapeutic target

Hongbing Zhang1, 2, *, #, Yalin Mu3, #, Hongsong Li1, 2, #, Xiaogang Li4, 5, *   

  1. 1 Department of Ophthalmology, Xi’an No. 1 Hospital, First Affiliated Hospital of Northwest University, Xi’an, Shaanxi Province, China;  2 Shaanxi Institute of Ophthalmology, Xi’an, Shaanxi Province, China;  3 Department of Ophthalmology, Yellow River Sanmenxia Hospital, Sanmenxia, Henan Province, China;  4 Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA;  5 Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA
  • Online:2026-04-15 Published:2025-07-25
  • Contact: Hongbing Zhang, PhD, zhanghongbing01@163.com; Xiaogang Li, PhD, li.xiaogang@mayo.edu.
  • Supported by:
    This work was supported by the Natural Science Foundation of Shaanxi Province (Key Program), No. 2021JZ-60 (to HZ).

摘要:

未折叠蛋白反应是一种细胞通路,当内质网被未折叠蛋白压垮时,它被激活以维持蛋白稳态并防止细胞死亡。然而,如果未折叠蛋白反应无法恢复内质网的平衡,就会触发促炎症和促死亡信号,目前一些研究者正在研究它们在视网膜退行性疾病中的作用。文章的目的是综述内质网应激的未折叠蛋白反应在视网膜退行性疾病中的作用。泛素化错误折叠蛋白的积累会导致蛋白质组迅速不稳定和细胞死亡。针对内质网应激缓解视网膜病变涉及多种策略,包括使用化学伴侣(如4-苯基丁酸和牛磺脱氧胆酸)来增强蛋白质折叠和减少内质网应激。影响内质网应激传感器的小分子调节剂,如增加内质网应激调节剂X-box结合蛋白1表达的调节剂,也是潜在的治疗药物。抑制肌醇要求跨膜激酶/内切酶 1(一种关键的内质网应激传感器)的 RNA 酶活性是另一类可防止有毒聚集体形成的药物。激活 PPAR 和 FXR 等核受体也能缓解内质网应激。此外,通过诱导自噬或限制去泛素化酶来增加蛋白质分解,也有助于清除折叠错误的蛋白质。涉及内质网应激靶向药物和基因疗法的综合疗法也在探索之中。尽管有这些潜在的治疗策略,但针对视网膜变性的内质网应激治疗仍面临巨大挑战,进一步的研究对于阐明人类视网膜疾病的机制和开发有效、耐受性良好的药物至关重要。针对肌醇要求跨膜激酶/内切酶1和 X-box 结合蛋白 1 的现有药物的使用与不良反应有关,这阻碍了它们的临床转化。此外,内质网应激传感器下游的信号传导也会导致耐药性。解决这些局限性对于开发可有效用于治疗视网膜营养不良症的药物至关重要。总之,虽然未折叠蛋白反应是治疗视网膜变性疾病的一个很有前景的靶点,但要克服目前的局限性并提高患者的治疗效果,还必须进行更多的研究和开发。

https://orcid.org/0000-0002-1350-4502 (Hongbing Zhang); https://orcid.org/0000-0001-8135-243X (Xiaogang Li)

关键词: 年龄相关性黄斑变性, 自噬, 糖尿病视网膜病变, 内质网应激, 炎症, 炎性体, 突变, 线粒体疾病, 核受体, 感光细胞, 蛋白稳态, 蛋白毒性应激, 视网膜疾病, 视网膜色素变性

Abstract: The unfolded protein response is a cellular pathway activated to maintain proteostasis and prevent cell death when the endoplasmic reticulum is overwhelmed by unfolded proteins. However, if the unfolded protein response fails to restore endoplasmic reticulum homeostasis, it can trigger proinflammatory and pro-death signals, which are implicated in various malignancies and are currently being investigated for their role in retinal degenerative diseases. This paper reviews the role of the unfolded protein responsein addressing endoplasmic reticulumstress in retinal degenerative diseases. The accumulation of ubiquitylated misfolded proteins can lead to rapid destabilization of the proteome and cellular demise. Targeting endoplasmic reticulum stress to alleviate retinal pathologies involves multiple strategies, including the use of chemical chaperones such as 4-phenylbutyric acid and tauroursodeoxycholic acid, which enhance protein folding and reduce endoplasmic reticulum stress. Small molecule modulators that influence endoplasmic reticulum stress sensors, including those that increase the expression of the endoplasmic reticulum stress regulator X-box binding protein 1, are also potential therapeutic agents. Additionally, inhibitors of the RNAse activity of inositol-requiring transmembrane kinase/endoribonuclease 1, a key endoplasmic reticulum stress sensor, represent another class of drugs that could prevent the formation of toxic aggregates. The activation of nuclear receptors, such as PPAR and FXR, may also help mitigate ER stress. Furthermore, enhancing proteolysis through the induction of autophagy or the inhibition of deubiquitinating enzymes can assist in clearing misfolded proteins. Combination treatments that involve endoplasmicreticulum-stress-targeting drugs and gene therapies are also being explored. Despite these potential therapeutic strategies, significant challenges remain in targeting endoplasmic reticulum stress for the treatment of retinal degeneration, and further research is essential to elucidate the mechanisms underlying human retinal diseases and to develop effective, well-tolerated drugs. The use of existing drugs that target inositol-requiring transmembrane kinase/endoribonuclease 1 and X-box binding protein 1 has been associated with adverse side effects, which have hindered their clinical translation. Moreover, signaling pathways downstream of endoplasmic reticulum stress sensors can contribute to therapy resistance. Addressing these limitations is crucial for developing drugs that can be effectively used in treating retinal dystrophies. In conclusion, while the unfolded protein response is a promising therapeutic target in retinal degenerative diseases, additional research and development efforts are imperative to overcome the current limitations and improve patient outcomes.

Key words: age-related macular degeneration, autophagy, diabetic retinopathy, endoplasmic reticulum stress, inflammasome, inflammation, mitochondrial diseases, mutation, nuclear receptors, photoreceptor cells, proteostasis, proteotoxic stress, retinal diseases, retinitis pigmentosa